JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sgouros, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sgouros, G.
Journal of Nuclear Medicine Vol. 46 No. 1 (Suppl) 18S-27S
© 2005 by Society of Nuclear Medicine

Dosimetry of Internal Emitters

George Sgouros, PhD

Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, Maryland

Response and toxicity prediction is essential to rational implementation of cancer therapy. The biologic effects of radionuclide therapy are mediated via a well-defined physical quantity, the absorbed dose, which is defined as the energy absorbed per unit mass of tissue. The concepts, basic definitions, and different approaches to the clinical implementation of absorbed dose estimation are reviewed in this article. Ongoing efforts to improve the accuracy of dosimetry calculations are discussed, as well as studies examining the relationship between absorbed dose and response. Particular attention is placed on the marrow and kidney as dose-limiting organs. Finally, the potential role of radiobiologic modeling in helping to account for differences in dose rate and spatial distribution are reviewed. A treatment planning approach to radionuclide therapy will eventually require incorporation of biologic and radiobiologic considerations. Until such methods are developed and validated, absorbed dose remains an important variable—but still one of several— likely to predict response in an individual patient.

Key Words: radionuclide therapy • radiobiologic modeling • absorbed dose • treatment planning




This article has been cited by other articles:


Home page
JNMHome page
B. W. Wessels, M. W. Konijnenberg, R. G. Dale, H. B. Breitz, M. Cremonesi, R. F. Meredith, A. J. Green, L. G. Bouchet, A. B. Brill, W. E. Bolch, et al.
MIRD Pamphlet No. 20: The Effect of Model Assumptions on Kidney Dosimetry and Response--Implications for Radionuclide Therapy
J. Nucl. Med., November 1, 2008; 49(11): 1884 - 1899.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
P. Zanotti-Fregonara, C. Champion, R. Trebossen, R. Maroy, J.-Y. Devaux, and E. Hindie
Estimation of the {beta}+ Dose to the Embryo Resulting from 18F-FDG Administration During Early Pregnancy
J. Nucl. Med., April 1, 2008; 49(4): 679 - 682.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
M. Cremonesi, M. Ferrari, C. M. Grana, A. Vanazzi, M. Stabin, M. Bartolomei, S. Papi, G. Prisco, G. Martinelli, G. Paganelli, et al.
High-Dose Radioimmunotherapy with 90Y-Ibritumomab Tiuxetan: Comparative Dosimetric Study for Tailored Treatment
J. Nucl. Med., November 1, 2007; 48(11): 1871 - 1879.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
J. C. Pichardo, A. A. Trindade, J. M. Brindle, and W. E. Bolch
Method for Estimating Skeletal Spongiosa Volume and Active Marrow Mass in the Adult Male and Adult Female
J. Nucl. Med., November 1, 2007; 48(11): 1880 - 1888.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
A. R. Prideaux, H. Song, R. F. Hobbs, B. He, E. C. Frey, P. W. Ladenson, R. L. Wahl, and G. Sgouros
Three-Dimensional Radiobiologic Dosimetry: Application of Radiobiologic Modeling to Patient-Specific 3-Dimensional Imaging-Based Internal Dosimetry
J. Nucl. Med., June 1, 2007; 48(6): 1008 - 1016.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
G. Sgouros
Toward Patient-Friendly Cell-Level Dosimetry
J. Nucl. Med., April 1, 2007; 48(4): 496 - 497.
[Full Text] [PDF]


Home page
JNMHome page
W. Cai, K. Chen, K. A. Mohamedali, Q. Cao, S. S. Gambhir, M. G. Rosenblum, and X. Chen
PET of Vascular Endothelial Growth Factor Receptor Expression
J. Nucl. Med., December 1, 2006; 47(12): 2048 - 2056.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
J. M. Brindle, A. A. Trindade, A. P. Shah, D. W. Jokisch, P. W. Patton, J. C. Pichardo, and W. E. Bolch
Linear Regression Model for Predicting Patient-Specific Total Skeletal Spongiosa Volume for Use in Molecular Radiotherapy Dosimetry
J. Nucl. Med., November 1, 2006; 47(11): 1875 - 1883.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
M. Cremonesi, M. Ferrari, L. Bodei, G. Tosi, and G. Paganelli
Dosimetry in Peptide Radionuclide Receptor Therapy: A Review
J. Nucl. Med., September 1, 2006; 47(9): 1467 - 1475.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
G A Kaltsas, D Papadogias, P Makras, and A B Grossman
Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues
Endocr. Relat. Cancer, December 1, 2005; 12(4): 683 - 699.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
Y. Wu, X. Zhang, Z. Xiong, Z. Cheng, D. R. Fisher, S. Liu, S. S. Gambhir, and X. Chen
microPET Imaging of Glioma Integrin {alpha}v{beta}3 Expression Using 64Cu-Labeled Tetrameric RGD Peptide
J. Nucl. Med., October 1, 2005; 46(10): 1707 - 1718.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2005 by the Society of Nuclear Medicine.